ClinConnect ClinConnect Logo
Search / Trial NCT05865054

Vascular MRI Evaluation in Giant Cell Arteritis (VEGA)

Launched by UNIVERSITY OF PENNSYLVANIA · May 9, 2023

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

Temporal Arteritis Juvenile Temporal Arteritis Horton's Giant Cell Arteritis Horton's Disease Horton Giant Cell Arteritis Horton Disease Giant Cell Aortitis Giant Cell Aortic Arteritis Cranial Arteritis

ClinConnect Summary

**Trial Summary: Vessel Wall Enhancement in Giant Cell Arteritis**

This clinical trial is investigating how well magnetic resonance imaging (MRI) can help detect inflammation in the arteries that supply blood to the head, brain, and eyes in patients with Giant Cell Arteritis (GCA). GCA, also known as temporal arteritis, can cause serious symptoms like headaches, vision problems, and jaw pain. The study is currently looking for participants who either have a new diagnosis of GCA or are experiencing a relapse of their condition with new or worsening symptoms. To be eligible, participants should have symptoms related to GCA and must be within 14 days of starting or increasing treatment with steroid medications, like prednisone.

Participants in the trial will have an MRI to check for signs of inflammation in their arteries. It's important to know that people with certain medical conditions, such as having a pacemaker or severe kidney issues, may not be able to participate. Additionally, individuals who are pregnant, nursing, or have significant anxiety about being in small spaces (claustrophobia) are also excluded. By participating, individuals will have the opportunity to contribute to research that may improve understanding and treatment of GCA for future patients.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age 50 years or older
  • First presentation of suspected GCA
  • New or worsening cranial manifestations within 4 weeks of enrollment concerning for active GCA
  • Elevated CRP greater than 1.0 mg/dl
  • Plan to undergo temporal artery biopsy or ultrasound for diagnosis
  • Exclusion Criteria:
  • * Contra-indication to receiving MRI including:
  • Implanted medical devices, pacemaker, and metallic foreign fragments inside body/orbits Known gadolinium allergy Women who are pregnant or nursing
  • Absence of cranial symptoms related to GCA (e.g., only large vessel GCA)

About University Of Pennsylvania

The University of Pennsylvania, a prestigious Ivy League institution located in Philadelphia, is renowned for its commitment to advancing medical research and improving healthcare outcomes. As a clinical trial sponsor, the university leverages its extensive resources, interdisciplinary expertise, and cutting-edge facilities to conduct innovative studies across various therapeutic areas. With a focus on translating scientific discoveries into clinical applications, the University of Pennsylvania fosters collaborations among leading researchers, clinicians, and industry partners, ensuring rigorous trial design and adherence to ethical standards. Through its dedication to excellence in research and education, the university plays a pivotal role in shaping the future of medicine.

Locations

Philadelphia, Pennsylvania, United States

Patients applied

0 patients applied

Trial Officials

Rennie Rhee, MD

Principal Investigator

University of Pennsylvania

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported